The HLA-A*02:01–gp100280–288 peptide complex is, therefore, an attractive target for anti-melanoma therapy [89,90]; however, a limitation is that only about 50% of Caucasian individuals are HLA-A*02:01 positive [92]. Here, HLA-A is linked to melanoma.